<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884532</url>
  </required_header>
  <id_info>
    <org_study_id>11012</org_study_id>
    <nct_id>NCT01884532</nct_id>
  </id_info>
  <brief_title>ASR-XL Metal-on-Metal 522 Post-Market Surveillance Study</brief_title>
  <official_title>Cross-Sectional, Multi-Center Evaluation of 6 Year Metal Ion Trends for ASR-XL Total Hip Replacement System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DePuy Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DePuy Orthopaedics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate blood metal ion levels as a function of
      time of implantation for the ASR-XL MoM system.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Chromium serum ion level across time intervals</measure>
    <time_frame>Pre-operatively through 6 years</time_frame>
    <description>To compare the chromium serum ion levels in the patient population from pre-operatively through 6 years post-operatively in a 1-way ANOVA. This is a cross-sectional study so each time interval (2 through 6 years) will be a different cohort of patients. Notes: Pre-operative values are being collected via a separate protocol. There is no 1 year data available for this product due its withdrawal from the market.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Chromium whole blood ion level across time intervals</measure>
    <time_frame>Pre-operatively through 6 years</time_frame>
    <description>To compare the chromium whole blood ion levels in the patient population from pre-operatively through 6 years post-operatively in a 1-way ANOVA. This is a cross-sectional study so each time interval (2 through 6 years) will be a different cohort of patients. Notes: Pre-operative values are being collected via a separate protocol. There is no 1 year data available for this product due its withdrawal from the market.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cobalt serum ion level across time intervals</measure>
    <time_frame>Pre-operatively through 6 years</time_frame>
    <description>To compare the cobalt serum ion levels in the patient population from pre-operatively through 6 years post-operatively in a 1-way ANOVA. This is a cross-sectional study so each time interval (2 through 6 years) will be a different cohort of patients. Notes: Pre-operative values are being collected via a separate protocol. There is no 1 year data available for this product due its withdrawal from the market.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cobalt whole blood ion level across time intervals</measure>
    <time_frame>Pre-operatively through 6 years</time_frame>
    <description>To compare the cobalt whole blood ion levels in the patient population from pre-operatively through 6 years post-operatively in a 1-way ANOVA. This is a cross-sectional study so each time interval (2 through 6 years) will be a different cohort of patients. Notes: Pre-operative values are being collected via a separate protocol. There is no 1 year data available for this product due its withdrawal from the market.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Poolability of data across stem types</measure>
    <time_frame>Pre-operatively through 6 years post-operatively</time_frame>
    <description>Within each of the primary analyses, the poolability of the data across stem types will be confirmed with a 2-way ANOVA model in which both time interval and stem type are independent variables. Note: Pre-operative data is being collected via a separate protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse local tissue reaction (ALTR)</measure>
    <time_frame>Pre-operatively through 6 years post-operatively</time_frame>
    <description>To determine trends in the incidence of ALTR over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant survivorship</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>To determine implant survivorship, where an implant is considered to be surviving when none of the total hip replacement (THR)system components have been removed or replaced, so that the original system with metal-on-metal (MoM) articulating surfaces remains intact. Implant survivorship will be analyzed in two ways: 1) for all revisions (for any reason)and 2) for revisions due to ALTR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify the incidence of ALTR among unrevised subjects</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>To identify the incidence of ALTR among unrevised subjects through physical examination and imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ion levels among revised subjects</measure>
    <time_frame>Pre-operatively through 6 years post-operatively</time_frame>
    <description>To compare cobalt and chromium ion level (prior to revision) vs. baseline for subjects who are revised. Note: Pre-operative levels are being obtained via a separate protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris Hip and HOOS analysis for pain, function and total score</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>To identify the incidence of pain or functional symptoms among unrevised subjects with a Harris Hip and HOOS evaluation. To compare cobalt and chromium ion levels for unrevised subject who are exhibiting pain or functional symptoms vs. unrevised subject who are not exhibiting pain or functional symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the association of adverse events with elevated ion levels</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>To investigate the association of adverse events with elevated cobalt and chromium ion levels. For each respective adverse event, to compare cobalt and chromium ion levels for subjects who have vs. subjects who have not exhibited the adverse event. For each respective adverse event category, to present summary statistics of cobalt and chromium ion levels for subjects who have vs. subjects who have not exhibited the adverse event, stratified by post-op time cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trending</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>Trends (over time since initial implant) will be evaluated for : 1) revisions (survivorship), 2) adverse events, 3) pain or functional symptoms (via Harris Hip and HOOS evaluations), 4) incidence of ALTR in unrevised subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient history and demographics and association with outcomes</measure>
    <time_frame>Throughout 6 years post-operatively</time_frame>
    <description>Patient demographic and subject history will be evaluated for association with: 1) higher metal ion levels and 2) risk of revision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modes and causes of implant failure</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>To evaluate modes and causes of implant failure based on an analysis of reasonably available explanted retrieved devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metal ion levels and association with reason for revision</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>To compare cobalt and chromium levels across the different reasons for revision.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of metal ion levels across subjects with vs. without ALTR</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>Cobalt and chromium ion levels will be compared for unrevised subjects who were not diagnosed with an ALTR vs. unrevised subjects who were diagnosed with an ALTR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ion level vs. baseline for ALTR subjects</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>To compare cobalt and chromium ion level vs. baseline for subjects who are diagnosed with ALTR. Note: Baseline measurements are being captured via a separate protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ion level change from first measurement for ALTR subjects</measure>
    <time_frame>Through 6 years post-operatively</time_frame>
    <description>Cobalt and chromium ion levels will be compared from first measurement to the time of revision (prior to revision) or the time of last follow-up visit in the study, whichever comes first, for subjects who are diagnosed with an ALTR.</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">146</enrollment>
  <condition>Adverse Local Tissue Reaction</condition>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>2 year post-op</arm_group_label>
    <description>Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 year post-op</arm_group_label>
    <description>Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 year post-op</arm_group_label>
    <description>Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 year post-op</arm_group_label>
    <description>Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 year post-op</arm_group_label>
    <description>Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ASR-XL Metal-on-Metal</intervention_name>
    <description>All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.</description>
    <arm_group_label>2 year post-op</arm_group_label>
    <arm_group_label>3 year post-op</arm_group_label>
    <arm_group_label>4 year post-op</arm_group_label>
    <arm_group_label>5 year post-op</arm_group_label>
    <arm_group_label>6 year post-op</arm_group_label>
    <other_name>ASR-XL</other_name>
    <other_name>ASR-XL MoM</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and serum samples are retained
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have undergone a total hip arthroplasty with the ASR-XL Metal-on-Metal device
        that are currently 2 to 6 years post-operative.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to (or capable of) provide written, voluntary consent to participate in the
             clinical investigation,

          2. Is willing and able to return for all protocol defined clinic visits,

          3. Subject has (or had, if previously revised) a combination of the following implants in
             the study hip:

               1. ASR-XL cup or ASR 300 cup

               2. XL femoral head

               3. ASR-XL tapered sleeve adapter

               4. One of the following stems

             i. S-ROM ii. Corail iii. Tri-Lock iv. AML v. Summit vi. Prodigy vii. C-Stem AMT

          4. Subject has high quality films available for review that were taken within 12 months
             of primary surgery of the following views:

               1. Standing AP-Pelvis

               2. Standing AP-Proximal Femur (if this view is not available but the AP-Pelvis shows
                  the entire implant and greater trochanter, that is also acceptable)

               3. Lauenstien Lateral Proximal Femur (Lateral-femur).

        Exclusion Criteria:

          1. The subject refuses to allow their medical records to be inspected by the Sponsor,
             representatives of the Sponsor, the medical office staff and/or representatives from
             the FDA

          2. The implanted hip components in the study hip (exclusive of cement), are not all DePuy
             components

          3. The femoral component is the ASR hemi or some other hemi device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary F Panozzo, BS</last_name>
    <role>Study Director</role>
    <affiliation>DePuy Synthes Joint Reconstruction</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnatti</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adverse Local Tissue Reaction</keyword>
  <keyword>Metal Ions</keyword>
  <keyword>Serum</keyword>
  <keyword>Whole Blood</keyword>
  <keyword>Metal-on-Metal</keyword>
  <keyword>Total Hip Arthroplasty</keyword>
  <keyword>ASR-XL Metal-on-Metal</keyword>
  <keyword>Revised ASR-XL Metal-on-Metal</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

